Compare FLL & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | INKT |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 59.4M |
| IPO Year | 2014 | 2021 |
| Metric | FLL | INKT |
|---|---|---|
| Price | $1.38 | $12.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.13 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 198.9K | 17.1K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $302,376,000.00 | N/A |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $1.36 | $8.48 |
| 52 Week High | $3.37 | $15.35 |
| Indicator | FLL | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 23.31 | 53.80 |
| Support Level | N/A | $10.84 |
| Resistance Level | $2.74 | $12.35 |
| Average True Range (ATR) | 0.12 | 0.65 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 4.38 | 53.33 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.